Phase 4Completed

C-Reactive Protein (CRP) in Obese Diabetic Women

Interventions Study for the Control of Diabetes Mellitus Type 2 in Obese Women

Sponsor
AstraZeneca (Industry)
Enrollment
100 planned
Conditions
Diabetes Mellitus, Type 2
Interventions
Rosuvastatin; improvement of lipid profile
Ages
adults, older adults
Registry
NCT00262548

Full record on ClinicalTrials.gov

From the registry

The purpose of this study is to determine whether treatment with rosuvastatin for 6 months in obese type 2 diabetic women will improve their lipid profiles and thus prevent the progression to cardiovascular disease.

Primary outcomes

  • Patients will be receiving rosuvastatin/placebo for 6 months
  • They will have baseline laboratory parameters taken such as glycemia
  • HbA1c (glycosylated hemoglobin), low-density lipoprotein cholesterol (LDL-C), computed tomography (CT), high-density lipoprotein cholesterol (HDL-C), C-reactive protein (CRP), and retaken every 3 months
  • Every month, patients will be evaluated at the clinic

History

  1. Last registry update

  2. Registered

  3. Started